A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2012

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Therapeutic Use
  • Acronyms BOLD
  • Most Recent Events

    • 10 Apr 2012 Actual patient number changed from 35 to 21 as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 10 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top